Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14, 02-776 Warsaw, Poland.
Department of Transfusion Medicine, Institute of Hematology and Transfusion Medicine, Indiry Gandhi 14, 02-776 Warsaw, Poland.
Transfus Apher Sci. 2024 Jun;63(3):103912. doi: 10.1016/j.transci.2024.103912. Epub 2024 Mar 14.
The Institute of Hematology and Transfusion Medicine (IHTM) in Warsaw has produced autologous serum eye drops (ASEDs) for the treatment of Dry Eye Syndrome (DES) since 1991. In 2019, IHTM introduced allogeneic tears (alloSEDs) for patients on long-term treatment.
114 patients who applied alloSEDs were included in the study.They were asked to complete the OSDI questionnaire before and after using ASEDs and 100 units of alloSEDs drops from each donation. The OSDI index rates DES severity (0 no symptoms; 100 severe). We also compared the content of IL-1β, IL-2, IL- 6, IL-10 and VEGF in ASEDs (38 samples) and alloSEDs (15 serum samples). The study data covered the 2019-2022 period.
114 patients participated in the study. We compared the the effectiveness of ASEDs and alloSEDs. The average, OSDI dropped from 68.42 ± 5,86 (before application) to 51.05 ± 19,06 (after application). Data from the questionnaires (prepared at IHTM) completed and returned (41/114) present the most common indications for the use of serum drops, including DES with no underlying disease, DES secondary to GvHD (Graft versus Host Disease), Sjögren's Syndrome (SS). The study reported higher cytokine levels associated with disease entities such as SS. After application of drops with high cytokine levels, patients reported adverse reactions such as sand under the eyelids, impaired visual acuity, and worse eye lubrication.
AlloSEDs with acceptably low values of pro-inflammatory cytokines and sufficiently high levels of VEGF growth factor may contribute to alleviation of inflammatory eye symptoms.
华沙血液学与输血研究所（IHTM）自 1991 年以来一直生产用于治疗干眼症（DES）的自体血清滴眼液（ASED）。2019 年，IHTM 为长期接受治疗的患者引入了同种异体眼泪（alloSED）。
共有 114 名应用 alloSED 的患者被纳入本研究。他们被要求在使用 ASED 和 100 个单位的 alloSED 滴液后，从每个捐赠者的每个滴眼剂填写 OSDI 问卷。OSDI 指数评估 DES 的严重程度（0 无症状；100 严重）。我们还比较了 ASED（38 个样本）和 alloSED（15 个血清样本）中 IL-1β、IL-2、IL-6、IL-10 和 VEGF 的含量。研究数据涵盖了 2019-2022 年期间。
共有 114 名患者参与了研究。我们比较了 ASED 和 alloSED 的疗效。平均而言，OSDI 从 68.42±5.86（应用前）下降到 51.05±19.06（应用后）。来自（由 IHTM 准备并返回的）调查问卷的数据（114 名患者中的 41 名）提供了使用血清滴眼剂的最常见指征，包括无潜在疾病的 DES、继发于 GvHD（移植物抗宿主病）的 DES、干燥综合征（SS）。该研究报告了与 SS 等疾病实体相关的更高细胞因子水平。在应用高细胞因子水平的滴眼剂后，患者报告了不良反应，如眼睑下有沙粒、视力受损和眼睛润滑性更差。
具有可接受的低水平促炎细胞因子和足够高水平的 VEGF 生长因子的 alloSED 可能有助于缓解眼部炎症症状。
